Global healthcare company BTG has acquired Roxwood Medical, a provider of cardiovascular speciality catheters used to treat patients with severe coronary and peripheral artery disease.
John Sylvester, BTG’s chief commercial officer, said: “This bolt-on acquisition continues to build BTG’s strength in the interventional vascular space, further expanding our portfolio of differentiated minimally invasive vascular technologies.”
The healthcare group will pay $65m on closing and a further $15m should Roxwood achieve certain commercial milestones.
Mehrdad Farhangnia, chief executive officer at Roxwood, said: “This is an exciting new chapter for the team at Roxwood and further testament to the utility of the anchoring and microcatheter platforms.
“With the expanded commercial and clinical reach of BTG, these minimally invasive tools can help far more clinicians successfully treat patients with severe arterial blockages.”